Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.305 +0.045 (+1.06%)
Streaming Delayed Price Updated: 3:47 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,230,617
Open 4.300
Bid (Size) 4.300 (1,300)
Ask (Size) 4.310 (2,400)
Prev. Close 4.260
Today's Range 4.210 - 4.400
52wk Range 0.8000 - 5.780
Shares Outstanding 160,028,388
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ironwood Pharmaceuticals Q2 Earnings Call Highlights ↗
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its... 
Via MarketBeat
Topics Earnings
Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss ↗
Via Chartmill

Performance

YTD
+0.8%
+0.8%
1 Month
-3.7%
-3.7%
3 Month
+3.2%
+3.2%
6 Month
-3.3%
-3.3%
1 Year
+434.8%
+434.8%

More News

Read More
News headline image
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals (NASDAQ:IRWD) Crushes Q1 Estimates with 97% LINZESS Surge ↗
Via Chartmill
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Q4 Miss but Provides Robust 2026 Outlook ↗
Via Chartmill
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template ↗
Via Chartmill
News headline image
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks Trading Near $5 With Massive Earnings Upside ↗
Via MarketBeat
News headline image
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating ↗
Via MarketBeat

Frequently Asked Questions

Is Ironwood Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Ironwood Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Ironwood Pharmaceuticals, Inc. - Class A Common Stock trade on?
Ironwood Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ironwood Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Ironwood Pharmaceuticals, Inc. - Class A Common Stock is IRWD on the Nasdaq Stock Market
What is the current price of Ironwood Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Ironwood Pharmaceuticals, Inc. - Class A Common Stock is 4.305
When was Ironwood Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Ironwood Pharmaceuticals, Inc. - Class A Common Stock was at 08/07/26 03:47 PM ET
What is the market capitalization of Ironwood Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Ironwood Pharmaceuticals, Inc. - Class A Common Stock is 688.92M
How many shares of Ironwood Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Ironwood Pharmaceuticals, Inc. - Class A Common Stock has 689M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.